title: Enhancement by ischemia of the risk of cardiac disorders, especially fibrillation, in regional anesthesia with bupivacaine.
abstract: The impairment of intraventricular conduction by bupivacaine may result in reentrant arrhythmias including ventricular fibrillation. The concentrations responsible for serious accidents are high (5.0 to 8.0 micrograms/ml), but likely to be lowered by myocardial ischemia which gives rise to similar disorders. Therefore we did an electrophysiological study of bupivacaine's effects in an ischemic area of the myocardium. Monophasic action potential (MAP) of the ventricular myocardium was recorded in 30 anesthetized, open-chest pigs. Conduction time and effective refractory period were also measured. Data were obtained during short periods (10-15 s) of pacing at 180 beats/min, but ventricular beats remained governed by the sinus node in the intervals. Ischemia was produced by occluding the left anterior descending coronary artery completely but transiently (up to 8 min), not far from its origin. Comparison was made between the effects of bupivacaine i.v. (n = 10), ischemia (n = 10) and both factors (n = 10). Two min after injection of bupivacaine 2.0 mg/kg (plasma levels 2.0-3.0 micrograms/ml), the duration of MAP was only slightly (7.5-15%) prolonged and its ischemia-induced shortening only slightly attenuated by bupivacaine. At the same time, conduction time was considerably (75-150%) lengthened and its ischemia-induced lengthening enhanced, so that ventricular fibrillation induced by coronary occlusion occurred sooner (about 100 instead of 300 s) in the presence of bupivacaine. Consequently, bupivacaine should be used only with caution in individuals whose myocardium is ischemic or liable to ischemia episodes.
authors.affiliation: Department of Medical Pharmacology, Claude Bernard University, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Freysz
authors.forename: Q
authors.initials: Q
authors.lastname: Timour
authors.forename: L
authors.initials: L
authors.lastname: Bertrix
authors.forename: J
authors.initials: J
authors.lastname: Loufoua-Moundanga
authors.forename: S
authors.initials: S
authors.lastname: Omar
authors.forename: G
authors.initials: G
authors.lastname: Faucon
mesh_terms: D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000765:Anesthesia, Conduction; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002045:Bupivacaine / Q000009:adverse effects* / Q000097:blood; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications* / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects / Q000502:physiology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects / Q000502:physiology; D012307:Risk Factors; D013552:Swine; D014693:Ventricular Fibrillation / Q000139:chemically induced* / Q000209:etiology*
chemical_list: D002045:Bupivacaine